Quinupristin/dalfopristin

Bibliography

• MATHAI D, LEWIS MT, KUGLER K, PFALLER MA, JONES RN, AMERICA SPGON: Antibacterial activity of 41 antimicrobials tested against over 2773 bacterial isolates from hospitalized patients with pneumonia: I - results from the SENTRY Antimicrobial Surveillance Program (North America, 1998). Diag. Microbiol Infect. Dis. (2001) 39:105–116.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, JONES RN, DOERN GV et al.: Survey of blood stream infections attributable to Gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada and Latin America from the SENTRY Surveillance Program. Diag. Microbiol Infect. Dis. (1999) 33:283–297.
   PubMed Web of Science ®Google Scholar
• ARCHIBALD L, PHILLIPS L, MONNET D, MCGOWAN JE, TENOVER FC, GAYNES R: Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. Clin. Drug Invest. (1997) 24:211–215.
   Google Scholar
• SURVEILLANCE. NNI: NNIS System Report October 1986 - April 1998. (June 1998).
   Google Scholar
• BRONZWAER SLAM, BUCHHOLZ U, KOOL JL, MONEN J, SCHRRIJNE-MAKERS P: EARSS activities and results: update. Euro. Surveil] (2001) 6(1):2–5.
   PubMedGoogle Scholar
• FLUIT AC, JONES ME, SCHMITZ FJ et al.: Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY Anti-microbial Surveillance Program, 1997 and 1998. Clin. Infect. Dis. (2000) 30:454–460.
   PubMed Web of Science ®Google Scholar
• BELL JM, TURNIDGE JD, PARTICIPANTS SA: High prevalence of oxacillin-resistant Staphylococcus aureus isolates from hospitalized patients in Asia-Pacific and South Africa: results from SENTRY Antimicrobial Surveillance Program, 1998–1999. Antimicrob. Agents Chemother: (2002) 46:879–881.
   Google Scholar
• HANSMAN D, BULLEN MM: A resistant pneumococcus. Lancet (1967) 2:264–265.
   Web of Science ®Google Scholar
• APPELBAUM PC, BHAMJEE A, SCRAGG JN, HALLETT AF, BOWEN AJ, COOPER RC: Streptococcus pneumoniae resistant to penicillin and chloramphenicol. Lancet (1977) 2:995–997.
   PubMed Web of Science ®Google Scholar
• JACOBS MR, KOORNHOF HJ, ROBINS-BROWNE RM et al.: Emergence of multiply resistant pneumococci. N Engl. Med. (1978) 299(14):735–740.
   PubMed Web of Science ®Google Scholar
• BLONDEAU JM: A review of the comparative in vitro activity of 12 antimicrobial agents with a focus on 4 new 'respiratory quinolones'. Antimicrob. Chemother: (1999) 43 (Suppl. B):1–11.
   Google Scholar
• HO PL, QUE TL, TSANG DN, NG TK, CHOW KH, SETO WH: Emergence of fluoroquinolone resistance among multiple resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob. Agents Chemother: (1999) 43(5):1310–1313. 1359 Expert Op/n. Pharmacother. (2002) 3(9)
   Google Scholar
• HO PL, YUNG RWH, TSANG DN, QUE TL, HO M, SETO WH: Increasing resistance of Streptococcus pneumoniaeto fluoroquinolones: results of a Hong Kong multicenter study in 2000. J. Antimicrob. Chemother. (2001) 48:659–665.
   PubMedGoogle Scholar
• DOERN GV, HEILMANN KP, HUYNH HK, RHOMBERG PR, COFFMAN SL, BRUEGGEMANN AB: Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob. Agents Chemother. (2001) 45:1721–1729.
   PubMed Web of Science ®Google Scholar
• LOW DE, DE AZAVEDO J, WEISS K et al.: Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrob. Agents Chemother. (2002) 46(5):1295–1301.
   PubMedGoogle Scholar
• COMMITTEE HICPA: Recommendations for preventing the spread of vancomycin resistance. Infect. Cont. Hosp. Epidemiol (1995) 16:10–113.
   Google Scholar
• EDMOND MB, WENZEL RP: Vancomycin-resistant Staphylococcus aureus: perspectives on measures needed for control. Ann. Intern. Med. (1996) 124:329–334.
   PubMed Web of Science ®Google Scholar
• HIRAMATSU K, HANAKI H, INO T, YABUTA K, OGURI T, TENOVER FC: Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother: (1997) 40:135–146.
   PubMed Web of Science ®Google Scholar
• SMITH TL, PEARSON ML, WILCOX KR et al.: Emergence of vancomycin resistance in Staphylococcus aureus. N Engl. .1. Med. (1999) 340(7):493–501.
   Google Scholar
• FRIDKIN SK: Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin. Infect. Dis. (2001) 32:108–115.
   PubMed Web of Science ®Google Scholar
• JOHNSON DM, ERWIN ME, BARRETT MS, BRIGGS-GOODING B, JONES RN: Antimicrobial activity of ten macrolide, lincosamine and streptogramin drugs tested against Legionella species. Eur: Clin. Microbiol Infect. Dis. (1992) 11:751–755.
   PubMed Web of Science ®Google Scholar
• ALCAIDE F, CARRATALA J, LINARES J,GUDIOL F, MARTIN R: In vitro activities of eight macrolide antibiotics and RP-59500 (quinupristin/dalfopristin) against viridans group streptococci isolated from blood of neutropenic cancer patient. Antimicrob. Agents Chemother: (1996) 40:2117–2120.
   Google Scholar
• SHONEKAN D, HAND WERGER S, MILDVAN D: Comparative M vitro activities of RP59500 (quinupristin/ dalfopristin), CL329, 998, CL 331, 002, trovafloxacin, clinafloxacin teicoplanin and vancomycin against Gram-positive bacteria. Antimicrob. Chemother. (1997) 39:405–409.
   Google Scholar
• SAMBATAKOU H, GIAMARELLOS-BOURBOULIS EJ, GRECKA P et al: In vitro activity land killing effect of quinupristin/dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interactions with rifampin and ciprofloxacin against methicillin-resistant isolates. Antimicrob. Chemother. (1998) 41:349–355.
   Google Scholar
• HOBAN DJ, WESHNOWESKI B, PALATNICK L, ZHANEL GG, DAVIDSON RJ: In vitro activity of streptogramin RP 59500 against staphylococci, including bactericidal kinetic studies. Antimicrob. Chemother: (1992) 30(Suppl. A):59–65.
   Google Scholar
• SCHWALBE RS, MCINTOSH AC, QAIYUMI S et al.: In vitro activity of LY333328, an investigational glycopeptide antibiotic, against Enterococci and Staphylococci. Antimicrob. Agents Chemother: (1996) 40:2416–2419.
   Google Scholar
• BRUMFITT W, HAMILTON-MILLER JMT, SHAH S: In vitro activity of RP59500, a new semisynthetic streptogramin antibiotic, against Gram-positive bacteria. Antimicrob. Chemother. (1992) 30(Suppl. A):29–37.
   Google Scholar
• RISTOW TA, NOSKIN GA, WARREN JR et al.: In vitro activity of RPR59500 (quinupristin/dalfopristin) and ramoplanin against vancomycin-resistant Enterococcus faecium. Microb. Drug Resist. (1995) 1:335–339.
   PubMed Web of Science ®Google Scholar
• JOHNSON CC, SLAVOSKI L, SCHWARTZ M et al: In vitro activity of RP 59500 (quinupristin/dalfopristin) against antibiotic-resistant strians of Strepto-coccus pneumoniae and Enterococci Diag. Microbial. Infect. Dis. (1995) 21:169–173.
   PubMed Web of Science ®Google Scholar
• LAMB HM, FIGGITT DP, FAULDS D: Quinupristin/dalfopristin - a review of its use in the management of serious Gram-positive infections. Drugs (1999) 57(6):1061–1097.
   Google Scholar
• WISE R, ANDREWS JM, BOSWELL F et al.: The M vitro activity of linezolid (U-100766) and tentative breakpoints. Antimicrob. Chemother. (1988) 42:721–728.
   Google Scholar
• INOUE M, OKAMOTO R, OKUBO T et al.: Comparative M vitro activity of RP59500 against clinical bacterial isolates. Antimicrob. Chemother. (1992) 30(Suppl. A):45–51.
   Google Scholar
• HERSHBERGER E, AESCHLIMANN JR, MOLDOVAN T et al.: Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by time-kill curve methods. Antimicrob. Agents Chemother. (1999) 43:717–721.
   PubMed Web of Science ®Google Scholar
• PFEIL E, WEIDERMANN B: Pharmacodynamic of quinupristin/ dalfopristin (Q-D) against MSSA and MRSA in comparison to other antibacterial agents. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego, CA, USA(24–27 September 1998). Abstract 11.
   Google Scholar
• FANTIN B, LECLERCQ R, MERLE Y et al.: Critical influence of resistance to streptogramin B-type antibiotics on activity of RP59500 (quinupristin/dalfopristin) in experimental endocarditis due to Staphylococcus aureus. Antimicrob. Agents Chemother: (1995) 39:400–405.
   Google Scholar
• ENTENZA JM, DRUGEON H, GLAUSER MP, MOREILLON P: Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP59500. Antimicrob. Agents Chemother: (1995) 39:1419–1424.
   Google Scholar
• BOSWELL FJ, SUNDERLAND J, ANDREWS JM, WISE R: Time-kill kinetics of quinupristin/dalfopristin on Staphylcoccus aureus with and without a raised MBC evaluated by two methods.' Antimicrob. Chemother. (1997) 39(Suppl. A):29–32.
   Google Scholar
• RYBAK MJ, HOULIHAN HH, MERCIER RC, KAATZ GW: Pharmacodynamics of RP59500 (quinupristin/dalfopristin) administered by intermittent versus continuous infusion against Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model. Antimicrob. Agents Chemother. (1997) 41:1359–1363.
   PubMedGoogle Scholar
• HILL RL, SMITH CT, SEYED-AKHAVANI M, CASEWELL MW: Bactericidal and inhibitory activity of quinupristin/dalfopristin against vancomycin and gentamicin-resistant Enterococcus faecium. Antimicrob. 1360 Expert Op/n. Pharmacother. (2002) 3(9) Chemother. (1997) 39(Suppl. A):23–28.
   Google Scholar
• COLLINS LA, MALANOSKI GJ, ELIOPOULOS GM et al.: In vitro activity of RPR59500 an injectable streptogramin antibiotic, against vancomycin-resistant Gram-positive organisms. Antimicrob. Agents Chemother. (1993) 37:598–601.
   PubMed Web of Science ®Google Scholar
• FASS RJ: In vitro activity of RP59500, a semisynthetic injectable pristinamycin, against staphylcocci, streptococci and enterococci. Antimicrob. Agents Chemother: (1991) 34:553–559.
   Google Scholar
• WILLIAMS J, MASKELL JP, WHILEY AC, SEFTON AM: Comparative in vitro activity of quinupristin/dalfopristin against Enterococcus spp. Antimicrob. Chemother. (1997) 39\(Suppl. 441–46.
   Google Scholar
• AESCHLIMANN JR, ZERVOS MJ, RYBAK MJ: Treatment of vancomycin-resistant Enterococcus faeciumwith RP59500 (quinupristin/dalfopristin) adminstered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetations. Antimicrob. Agents Chemother. (1998) 42:2710–2717.
   PubMedGoogle Scholar
• MATSUMURA S, SIMOR AE: Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/ dalfopristin, doxycycline and rifampin: a synergistic drug combination. Clin. Infect. Dis. (1998) 27:1554–1556.
   PubMed Web of Science ®Google Scholar
• LORIAN V, FERNANDES F: Synergic activity of vancomycin-quinupristin/ dalfopristin combination against Enterococcus fad:turn.' Antimicrob. Chemother. (1997) 39(Suppl. A):63–66.
   Google Scholar
• BRISSON-NOEL A, TRIEU-CUOT P, COURVALIN P: Mechanism of action of spiramycin and other macrolides. Antimicrob. Chemother. (1988) 22(Suppl. B):13–23.
   Google Scholar
• WEISBLUM B: Inducible resistance to macrolides, lincosamides and streptogramin type B antibiotics: the resistance phenotype, its biological diversity and structural elements that regulate expression - a review. Antimicrob. Chemother. (1985) 16\(Suppl. 463–90.
   Google Scholar
• MENNINGER JR: Functional consequences of binding macrolides to ribosomes.J. Antimicrob. Chemother. (1985) 16(Suppl. A):23–34.
   Google Scholar
• RETSEMA JA, GIRARD AE, SCHELKLY W et al.: Spectrum and mode of action of azithromycin (CP-62, 993), a new 15- embered-ring macrolide with improved potency against Gram-negative organisms. Antimicrob. Agents Chemother: (1987) 31:1939–1947.
   Google Scholar
• EADY EA, ROSS JI, COVE JH: Multiple mechanisms of erythromycin resistance. Antimicrob. Chemother: (1990) 26:461–465.
   Web of Science ®Google Scholar
• AMSDEN GW: Pneumococcal macrolide resistance - myth or reality?,/, Antimicrob. Chemother: (1999) 44(1):1–6.
   Google Scholar
• LINA L, QUAGLIA A, REVERDY ME et al.: Distribution of genes encoding resistance to macrolides, lincosamides and streptogramins among staphylococci. Antimicrob. Agents Chemother: (1999) 43:1062–1066.
   PubMed Web of Science ®Google Scholar
• LECLERCQ R, NANTAS L, SOUSSY CJ et al: Activity of RP59500, a new parenteral semisynthetic streptogramin, against staphylococci with various mechanisms of resistance to macrolide-lincosamide-streptogramin antibiotics. J. Antimicrob. Chemother. (1992) 30(Suppl. A):67–75.
   Google Scholar
• WERNER G, KLARE I, WITTE W: Association between quinupristin/ dalfopristin resistance in glycopeptide-resistant Enterococcus faecium and the use of additives in animal feed. Ear: I Clin. Microbial. Infect. Dis. (1998) 17:401–402.
   PubMed Web of Science ®Google Scholar
• BERGERON M, MONTAY G: The pharmacokinetics of quinupristin/ dalfopristin in laboratory animals and in humans.' Antimicrob. Chemother: (1997) 39(Suppl. A):129–138.
   Google Scholar
• ETIENNE SD, MONTAY G, LE LIBOUX A, FRYDMAN A, GARAUD JJ: A Phase I, double-blind, placebo-controlled study of the tolerance and pharmacokinetic behavior of RP 59500.1 Antimicrob. Chemother. (1992) 30(Suppl. A):123–131.
   Google Scholar
• CHEVALIER P, REY J, PASQUIER 0, ROUZIER-PANIS R, HARDING N, MONTAY G: Multiple-dose pharmacokinetics and safety of two regimens of quinupristin/dalfopristin (Synercid) in healthy volunteers.' Clin. Pharmacol (2001) 41(4):404–414.
   Google Scholar
• JOHNSON CA, TAYLOR CA, ZIMMERMAN SW et al: Pharmacokinetics of quinupristin/ dalfopristin in continuous ambulatory peritoneal dialysis patients. Antimicrob. Agents Chemother. (1999) 43(1):152–156.
   PubMedGoogle Scholar
• GAILLARD C, VAN CANTFORT J, MONTAY G et al.: Disposition of the radiolabelled streptogramin RP59500 fin healthy male volunteers. 32nd Intersdence Conference on Antimicrobial Agents and Chemotherapy Anaheim, CA, USA (11–14 October 1992). Abstract 1317.
   Google Scholar
• CHEVALIER P, REY J, PASQUIER 0 et al.: Pharmacokinetics of quinupristin/ dalfopristin in patients with severe chronic renal insufficiency. Clin. Phannacokin. (2000) 39(1):77–84.
   Google Scholar
• CHEVALIER P, REY J, BOUCHER E et al.: Open, comparative study of the pharmacokinetics and safety of a single dose of quinupristin/dalfopristin (Q/D, RP59500, Synercid) in subjects with hepatic cirrhosis and healthy volunteers. 20th International Congress of Chemotherapy Sydney, Australia (28 June-3 July, 1997). Abstract 41.
   Google Scholar
• LEFEBVRE P, GEARY B, REY J et al.: Open, comparative study of the pharmacokinetics and safety of a single dose of quinupristin/dalfopristin (RP 59500, Synercid) in healthy male and female volunteers. 20th International Congress of Chemotherapy Sydney, Australia, (28 June-3 July, 1997). Abstract 41.
   Google Scholar
• LEFEBVRE P, REY J, HARDING N: Open, comparative study of the pharmacokinetics and safety of a single dose of quinupristin/dalfopristin (Q/D, RP 59500, Synercid) in healthy and elderly volunteers and healthy young volunteers. 20th International Congress of Chemotherapy Sydney, Australia, (28 June-3 July, 1997). Abstract 43.
   Google Scholar
• LEFEBVRE P, REY J, MORGANROTH Jet al.: Open, comparative study of the pharmacokinetics and safety of a single dose of quinupristin/dalfopristin (Q/D, RP 59500, Synercid) in obese and in non-obese male subjects. 20th International Congress of Chemotherapy Sydney, Australia, (28 June-3 July, 1997). Abstract 42.
   Google Scholar
• BERTHAUD N, MONTAY G, CONRAD BJ, DESNOTTES JF: Bactericidal activity and kinetics of RP 59500 in a mouse model of Staphylococcus aureus septicemia. Antimicrob. Chemother. (1995) 36:365–373.
   Google Scholar
• AZOULAY-DUPUIS E, VALLEE L, VEBER B, POCIDALO JJ: Activity of RP59500, a new semi-synthetic streptogramin in mouse pneumonia induced by a macrolide-resistant strain of Streptococcus pneumoniae. 31st Interscience Conference of Antimicrobial Agents and Chemotherapy New Orleans, LA, USA (29 September-3 October 1991). Abstract 902.
   Google Scholar
• AZOULAY-DUPUIS E, VALLEE L, VEBER B, POCIDALO JJ: Efficacy of 1361 Expert Op/n. Pharmacother. (2002) 3(9) RP59500 a new semi-synthetic streptogramin against penicillin and multi-resistant strains of Streptococcus pneumoniae. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy Anaheim, CA, USA (11–14 October 1992). Abstract 329.
   Google Scholar
• CRAIG W, EBERT S: Pharmacodynamic activities of RP59500 in an animal infection model. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans, LA, USA (17–20 October, 1993). Abstract.
   Google Scholar
• L'HERITEAU F, ENTENZA JM, LACASSIN F, LEPORT C, GLAUSER MP, MOREILLON P: PR59500 prophylaxis of experimental endocarditis due to erythromycin-susceptible and -resistant isogenic pairs of viridans group Streptococci. Antimicrob. Agents Chemother: (1995) 39:1425–1429.
   Google Scholar
• CHAMBERS HF: Studies of RP59500 in vitro and in a rabbit model of aortic valve endocarditis caused by methicillin-resistsant Staphylococcus aureus. .1. Antimicrob. Chemother. (1992) 30 (Suppl. A):117–122.
   Google Scholar
• BOUANCHAUD DH: In vitro and in vivo synergic activity and fractional inhibitory concentration (FIC) of the components of a semisynthetic streptogramin, RP 59500.1 Antimicrob. Chemother: (1992) 30(Suppl. A):95–99.
   Google Scholar
• ZAK 0, O'REILLY T: Animal models in the evaluation of antimicrobial agents. Antimicrob. Agents Chemother: (1991) 35:1527–1531.
   Google Scholar
• ZARROUK V, BOZDOGAN B, LECLERCQ R, GARRY L, CARBON C, FANTIN B: Influence of resistance to streptogramin A type antibiotics on the activity of quinupristin/dalfopristin in vitro and in experimental endocarditis due to Staphylococcus aureus Antimicrob. Agents Chemother. (2000) 44(5):1168–1173.
   PubMedGoogle Scholar
• FANTIN B, LECLERCQ R, OTTAVIANI M et al.: In vivo activities and penetration of the two components of the streptogramin RP 59500 in cardiac vegetations of experimental endocarditis. Antimicrob. Agents Chemother. (1994) 38:432–437.
   PubMed Web of Science ®Google Scholar
• ZARROUK V, BOZDOGAN B, LECLERCQ R et al.: Activities of the combination of quinupristin/dalfopristin with rifampin in vitro and in experimental endocarditis due to Staphylococcus aureus strains with various phenotypes of resistance to macrolide-lincosamide-streptogramin antibiotics. Antimicrob. Agents Chemother. (2001) 45(4):1244–1248.
   PubMedGoogle Scholar
• VOUILLAMOZ J, ENTENZA JM, FEGER C, GLAUSER MP, MOREILLON P: Quinupristin/dalfopristin combined with B-lactams for treatment of experimental endocarditis due to Staphylococcus aureus constitutively resistant to macrolide-lincosamide-streptogramin B antibiotics. Antimicrob. Agents Chemother. (2000) 44(7):1789–1795.
   PubMedGoogle Scholar
• VOUILLAMOZ J, ENTENZA JM, GIDDEY M, FEGER C, GLAUSER MP, MOREILLON P: High efficacy of synercid (SYN) combined with cefpirome (CP) against experimental endocarditis (EE) due to Staphylcoccus aureus resistant both to methicillin (MRSA) and to macrolide-lincosamide-streptogramins (MLSB-R). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, ON, Canada, (17–20 September 2000). Abstract 1004.
   Google Scholar
• VOUILLAMOZ J, TOMASZ A, SERADZKI K et al.: Efficacy of Synercid (SYN) and/or cefpirome (CP) in the treatment (Rx) of experimental endocarditis (EE) due to glycopeptide intermediate Staphylococcus aureus(GISA). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, ON, Canada, (17–20 September 2000). Abstract 1003.
   Google Scholar
• PAVIE J, ZARROUK V, LEFORT A et al: Activity of combination of quinupristin/ dalfopristin (Q-D) and vancomycin (VM) M vitro and in experimental endocarditis due to Staphylococcus aureus susceptible or resistant to quinupristin. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, ON, Canada, (17–20 September 2000). Abstract 1006.
   Google Scholar
• LOPEZ-FORNAS F, MARTINEZ-GARCIA F, PEREZ-SALMERON J et al: Comparative study of treatment with penicillin, ceftriaxone, trovafloxacin, quinupristin/dalfopristin and vancomycin in experimental endocarditis due to penicillin- and ceftriaxone-resistant Streptococcus pneumonia .1 Antimicrob. Chemother: (2001) 47(5):623–629.
   Google Scholar
• BOZIGAR PS, HERSHBERGER E, DONABEDIAN SM, ZERVOS MJ: Activity of quinupristin/dalfopristin along and in combination with ampicilllin in the treatment of vancomycin-resistant Enterococcus faecium and Staphylococcus aureus in experimental model of endocarditis in rabbits. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, ON, Canada, (17–20 September 2000).
   Google Scholar
• SALEH-MGHIR A, AMEUR N, MASSIAS L, FEGER C, CARBON C, CREMIEUX AC: Combination of synercid (Syn) and rifampin (Rif) is highly synergistic in experimental Staphylococcus aureus joint prosthesis infection. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, ON, Canada, (17–20 September 2000). Abstract 994.
   Google Scholar
• NICHOLS RK, GRAHAM DR, BARRIERE SL et al.: Treatment of hospitalized patients with complicated Gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin and vancomycin. Antimicrob. Chemother. (1999) 44:263–273.
   Google Scholar
• TALBOT GH, BARRIERE SL, CERWINKA S et al.: Efficacy of quinupristin/dalfopristin (Synercid, RP 59500) in the treatment of patients with positive blood cultures in global Phase III studies (abstract). 20th International Congress of Chemotherapy Sydney, Australia, (29 June-3 July, 1997).
   Google Scholar
• LINDEN PK, PASCULLE AW, MCDEVITT D, KRAMER DJ: Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteremia: comparison with a control cohort. J. Antimicrob. Chemother. (1997) 39\(Suppl. 4145–151.
   Google Scholar
• FAGON J, PATRICK H, HAAS DW et al:Treatment of Gram-positive nosocomial pneumonia: prospective random comparison of quinupristin/dalfopristin versus vancomycin. Am. J. Respic Clin. Care Med. (2000) 161:753–762.
   PubMed Web of Science ®Google Scholar
• BAUGHMAN R: Randomized, double blind, comparative multicenter study of quinupristin/dalfopristin (Q/D, RP 59500, Synercid) versus combination of ceftriaxone and erythromycin in the treatment of acute community-acquired bacterial pneumonia (CAP). 20th International Congress of Chemotherapy Sydney, Australia, (29 June-3 July, 1997).
   Google Scholar
• DREW RH, PERFECT JR, SRINATH L, KURKIMILIS E, DOWZICKY M, TALBOT GH: Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin/dalfopristin in patients intolerant of failing prior therapy. J. Antimicrob. Chemother. (2000) 46:775-784. 1362 Expert Op/n. Pharmacother. (2002) 3(9)
   Google Scholar
• MOELLERING RC Jr, REINHARDT J, BLUMBERG EA, BOMPART F, TALBOT GH: The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium.f. Antimicrob. Chemother. (1999) 44:251–261.
   PubMedGoogle Scholar
• JONES RN, KUGLER K, PFALLER MA, WINOKUR PL, GROUP SS: Character-istics of pathogens causing urinary tract infections in hospitals in North America: results from the SENTRY Antimicrobial Surveillance Program, 1997. Diag. Microbiol Infect. Dis. (1999) 35:55–63.
   PubMed Web of Science ®Google Scholar
• JARVIS WR, MARTONE WJ: Predominant pathogens in hospital infections.' Antimicrob. Chemother: (1992) 29(Suppl. A):19–24.
   Google Scholar
• DOERN GV, PFALLER MA, KUGLER K, FREEMAN J, JONES RN: Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY Antimicrobial Surveillance Program. Clin. Infect. Dis. (1998) 27:764–770.
   PubMed Web of Science ®Google Scholar
• SAHM DF, THORNSBERRY C, MAYFIELD DC, JONES ME, KARLOWSKY JA: In vitro activities of broad-spectrum cephalosporins against nonmeningeal isolates of Streptococcus pneumoniae: MIC interpretation using NCCLS M100-512 recommendations. Clin. Microbiol (2002) 40(2):669–674
   Google Scholar
• HOBAN DJ, DOERN GV, FLUIT AC, ROUSSEL-DELVALLEZ M, JONES RN: Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997–1999. Clin. Infect. Dis. (2001) 32\(Suppl. 2):581–93.
   Google Scholar
• BIEDENBACH DJ, WANGER A, JONESRN: Comparative M vitro activity of quinupristin/dalfopristin (RP 59500) tested against penicillin- and macrolide resistant pneumococci by the Etest.J. Antimicrob. Chemother. (1996) 38(3):553–555.
   Google Scholar
• PANKUCH GA, JACOBS MR, APPELBAUM PC: MIC and time-kill study of antipneumococcal activities of RPR 106972 (a new oral streptogramin), RP59500 (quinupristin/dalfopristin), pyostacine (RP 7293), penicillin G, cefotaxime, erythromycin and clarithromycin against 10 penicillin-susceptible and -resistant pneumococci. Antimicrob. Agents Chemother. (1996) 40:2071–2074.
   PubMedGoogle Scholar
• BARRY AL, FUCHS PC, BROWN SD: In vitro activity of an orally administered streptogramin (RPR 106, 972) compared to quinupristin/dalfopristin and erythromycin. Eur.Microbiol Infect. Dis. (1997)16:155–158.
   PubMed Web of Science ®Google Scholar
• BARRETT MS, JONES RN: In vitro activity of quinupristin/dalfopristin (RP59500) against a large collection of infrequently isolated or tested species. Diag. Microbiol Infect. Dis. (1996) 25:147–149.
   PubMed Web of Science ®Google Scholar
• LUHKT, HSUEH PR, TENG LJ et a/.: Quinupristin/dalfopristin resistance among Gram-positive bacteria in Taiwan. Antimicrob. Agents Chemother: (2000) 44:3374–3380.
   Google Scholar
• PEPPER C, HOY T, BENTLEY DP: BH-2/ Box ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br. Cancer (1997) 76(7):935–938.
   Google Scholar
• JAMJIAN C, BIEDENBACH DJ, JONES RN: In vitro evaluation of a novel ketolide antimicrobial agent, RU-64004. Antimicrob. Agents Chemother. (1997) 41:454–459.
   PubMedGoogle Scholar
• PUTNAM SD, JONES RN, JOHNSON DM, GROUP TQCS: In vitro anti-microbial activity and MIC quality control guidelines of RPR 106972 (RPR112807/ RPR106950): a novel orally administered streptogramin combination. Diag. Microbiol Infect. Dis. (1997) 28:139–147.
   PubMed Web of Science ®Google Scholar
• PANKUCH GA, LICHTENBERGER C, JACOBS MR, APPELBAUM PC: Antipneumococcal activities of RP59500 (quinupristin/dalfopristin), penicillin G, erythromycin and sparfloxacin determined by MIC and rapid time-kill methdologies. Antimicrob. Agents Chemother: (1996) 40:1653–1656.
   Google Scholar
• JORGENSEN JH, MCELMEEL ML: Activity of quinupristin/dalfopristin and its components against Haemophilus influenzae. I Antimicrob. Chemother: (1997) 39(Suppl. A):69–73.
   Google Scholar
• DUBOIS J, JOLY JR: In vitro activity of RP59500, a new synergic antibacterial agent, against Legionella spp. .1 Antimicrob. Chemother. (1992) 30 (Suppl. A):77–81.
   Google Scholar
• SOUSSY CJ, ACARJ, CLUZEL R et al: A collaborative study of the M vitro sensitivity of RP 59500 of bacteria isolated in seven hospitals in France. J. Antimicrob. Chemother. (1992) 30(Suppl. A):53–58.
   Google Scholar
• RENAUDIN H, BOUSSENS B, BEBEAR C: In vitro activity of RP59500 against Mycoplasmas. 31st Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, IL, USA (29 September-3 October 1991). Abstract 897.
   Google Scholar
• MULAZIMOGLU L, DRENNING SD, YU VL: In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin) and dalfopristin/quinupristin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob. Agents Chemother. (1996) 40:2428–2430.
   PubMed Web of Science ®Google Scholar
• GARCIA R, RAAD I: In vitro study of the potential role of quinupristin/dalfopristin in the treatment of catheter-related staphylococcal infections. Eur: .1. Clin. Microbiol Infect. Dis. (1996) 15(12):933–936.
   Google Scholar
• FUCHS PC, BARRY AL, BROWN SD: Bactericidal activity of quinupristin/ dalfopristin against Staphylococcus aureus clindamycin susceptibility as a surrogate indicator. Antimicrob. Agents Chemother: (2000) 44:2880–2882.
   PubMed Web of Science ®Google Scholar
• MOUTON JW, ENDTZ HP, DENHOLLANDER JG, VAN DEN BRAAK N, VERBRUGH HA: In vitro activity of quinupristin/dalfopristin compared with other widely used antibiotics against strains isolated from patients with endocarditis. I Antimicrob. Chemother. (1997) 39(Suppl. A):75–80.
   Google Scholar
• SCHEEL 0, LYON DJ, RODAHL VT, ADEYEMI-DORO FAB, LING TKW, CHENG AFB: In vitro susceptibility of isolates of methicillin-resistant Staphylococcus aureus 1988–1993.J Antimicrob. Chemother. (1997) 37:243–251.
   Google Scholar
• TUOHY MJ, WASHINGTON JA: Antimicrobial susceptibility of viridans group Streptococci. Diag. Microbiol Infect. Dis. (1997) 29:277–280.
   PubMed Web of Science ®Google Scholar
• MOORE LS, SCHNEIDER B, HOLLOWAY WJ: Minimal inhibitory concentrations and minimal bactericidal concentrations of quinupristin/dalfopristin against clinical isolates of Corynebacterium jeikeium and Listeria monocytogenes. .1. Antimicrob. Chemother. (1997) 39(Suppl. A):67–68.
   Google Scholar
• CORMICAN MG, JOHNSON DM, JONES RN: Activity of the quinupristin/ dalfopristin combination (RP-59500; Synercid) tested against vancomycin-resistant Enterococcus species. Diag. Microbiol Infect. Dis. (1996) 24:59–60.
   PubMed Web of Science ®Google Scholar
• MESSICK CR, PENDLAND SL: in vitro 1363 Expert Op/n. Pharmacother. (2002) 3(9) activity of chloramphenicol alone and in combination with vancomycin, ampicillin or RP59500 (quinupristin/dalfopristin) against vancomycin-resistant Enterococci Diag. Microbiol. Infect. Dis. (1997) 29:203–205.
   Google Scholar
• CARON F, GOLD HS, WENNERSTEN CB, FARRIS MG, MOELLERING RC Jr, ELIOPOULOS GM: Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin/dalfopristin) against vancomycin-resistant Enterococcus faecium. Antimicrob. Agents Chemother. (1997) 41:2749–2753.
   PubMedGoogle Scholar
• BONILLA HF, PERRI MB, KAUFFMAN CA, ZERVOS MJ: Comparative in vitro activity of quinupristin/dalfopristin against multidrug resistant Enterococcus faecium. Diag. Microbiol. Infect. Dis. (1996) 25:127–131.
   PubMed Web of Science ®Google Scholar